Demo
Close Language Tab
Locate us
Languages
J
Jagsonpal Pharmaceuticals Ltd Pharmaceuticals
₹ 220.14 -2.15 (-0.97%)
  • NSE
  • BSE

Overview

  • BSE Code 507789
  • NSE Symbol JAGSNPHARM
  • ISIN Demat INE048B01035
  • Book Value (₹) 35.91
  • Face Value (₹) 2.00
  • Market Cap (₹ Cr.) 1,441.92
  • P/E (TTM) 33.82
  • EPS (TTM) 6.39
  • Div Yield (%) 1.15

Performance

Today’s Low 219.01
Today’s High 223.10

220.14
52W Low 179.70
52W High 328.04

220.14
Open 222.90
Prev. Close 222.29
Volume 39,221.00

Corporate Actions

Jagsonpal Pharmaceuticals Limited - Shareholders meeting
Sep 24, 2025

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2025

Jagsonpal Pharmaceuticals Limited - Spurt in Volume
Apr 28, 2025

Significant increase in volume has been observed in Jagsonpal Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Jagsonpal Pharmaceuticals Limited has submitted their response.

About Jagsonpal Pharmaceuticals Ltd

Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd._x000D_ _x000D_ The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company._x000D_ _x000D_ The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future._x000D_ _x000D_ It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia._x000D_ _x000D_ In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity._x000D_
Founded: 1978
Chairman: Harsha Raghavan
Managing Director: Manish Gupta
Address: T-210 J, Shahpur Jat, New Delhi, New Delhi, 110049,

Frequently Asked Questions

What is the price of Jagsonpal Pharmaceuticals Ltd share today? +
How to buy stock of Jagsonpal Pharmaceuticals Ltd? +
What is the 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd? +
What is the PE ratio of Jagsonpal Pharmaceuticals Ltd? +
What is the Market Cap of Jagsonpal Pharmaceuticals Ltd? +